Dr Walter Jay Peet, MD | |
2145 Fairview Pl, Billings, MT 59102-0611 | |
(406) 245-2037 | |
Not Available |
Full Name | Dr Walter Jay Peet |
---|---|
Gender | Male |
Speciality | Plastic Surgery |
Location | 2145 Fairview Pl, Billings, Montana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1538593934 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | 3818 (Montana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Walter Jay Peet, MD 2145 Fairview Pl, Billings, MT 59102-0611 Ph: (406) 245-2037 | Dr Walter Jay Peet, MD 2145 Fairview Pl, Billings, MT 59102-0611 Ph: (406) 245-2037 |
News Archive
Asterias Biotherapeutics, Inc., a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today simplified its capital structure through the previously announced Asset Swap with BioTime, Inc.
Asymptomatic focal hypoechoic changes in the patellar and achilles tendons moderately increase the risk for future injury in professional dancers, show study findings.
Lung adenocarcinomas in people who have never smoked show greater genome instability than those in smokers, supporting the theory that lung cancer in never smokers arises through different pathways, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.
Many medical tests that once required sending samples to a laboratory and waiting for results can now be rapidly performed at the patient's bedside. As these point-of-care testing (POCT) technologies are increasingly integrated into patient care, careful attention is needed to protect patient safety and avoid medical errors, according to this month's special issue of Point of Care: The Journal of Near-Patient Testing & Technology.
Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPathâ„¢ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States.
› Verified 8 days ago